Ligusticum chuanxiong and Paeonia lactiflora : a review of their regulation of iron metabolism and ferroptosis in atherosclerosis therapy.
Chuanxiong (Ligusticum chuanxiong Hort.) and Chishao (Paeonia lactiflora Pall.) are widely used in Traditional Chinese Medicine (TCM) for their ability to promote blood circulation and resolve blood stasis, particularly in the treatment of cardiovascular diseases such as atherosclerosis (AS).
This review systematically summarizes the potential mechanisms by which L. chuanxiong and P. lactiflora modulate iron metabolism, inhibit ferroptosis, and enhance blood flow, offering innovative strategies for the treatment of AS.
A comprehensive literature search was performed using databases such as PubMed, Web of Science, and CNKI. We implemented a narrative review with explicit search strategies across regional databases that included specific keywords related to the pharmacological effects of Chuanxiong and Chishao, particularly their roles in iron metabolism and ferroptosis. Studies were selected based on predefined inclusion criteria, ensuring relevance and quality. The data were organized to summarize the mechanisms of action and therapeutic potential of these substances, while also incorporating insights from traditional medical texts, including classical TCM literature. Specific search strategy: SU=(("Atherosclerosis" [MeSH] OR "Atherosclerotic plaque" [Title/Abstract] OR "AS" [Title/Abstract] OR "Arteriosclerosis" [Title/Abstract]) AND ("Chuanxiong" [Title/Abstract] OR "Ligusticum chuanxiong" [MeSH]) AND ("Chishao" [Title/Abstract] OR "Paeonia lactiflora" [MeSH])) AND (("iron metabolism" [Title/Abstract] OR "ferroptosis" [MeSH] OR "lipid peroxidation" [Title/Abstract]) OR ("JAK-STAT pathway" OR "PI3K/AKT" OR "MAPK/NF-κB" OR "GPX4" [Title/Abstract]) AND ("randomized controlled trial" [Publication Type] OR "in vitro" [Title/Abstract] OR "in vivo" [Title/Abstract] OR "clinical study" [Title/Abstract])).
Ligusticum chuanxiong: and P. lactiflora modulate iron homeostasis by suppressing hepcidin and enhancing ferroportin, inhibit ferroptosis via GPX4 activation and System Xc- upregulation, and mitigate oxidative stress/inflammation through ROS scavenging and NF-κB suppression, collectively reducing atherosclerotic plaque instability.
Chuanxiong and Chishao demonstrate significant potential as therapeutic agents for AS by targeting iron metabolism and ferroptosis. Their traditional use in TCM is supported by modern pharmacological evidence, highlighting their potential for integration into modern therapeutic frameworks.
This review systematically summarizes the potential mechanisms by which L. chuanxiong and P. lactiflora modulate iron metabolism, inhibit ferroptosis, and enhance blood flow, offering innovative strategies for the treatment of AS.
A comprehensive literature search was performed using databases such as PubMed, Web of Science, and CNKI. We implemented a narrative review with explicit search strategies across regional databases that included specific keywords related to the pharmacological effects of Chuanxiong and Chishao, particularly their roles in iron metabolism and ferroptosis. Studies were selected based on predefined inclusion criteria, ensuring relevance and quality. The data were organized to summarize the mechanisms of action and therapeutic potential of these substances, while also incorporating insights from traditional medical texts, including classical TCM literature. Specific search strategy: SU=(("Atherosclerosis" [MeSH] OR "Atherosclerotic plaque" [Title/Abstract] OR "AS" [Title/Abstract] OR "Arteriosclerosis" [Title/Abstract]) AND ("Chuanxiong" [Title/Abstract] OR "Ligusticum chuanxiong" [MeSH]) AND ("Chishao" [Title/Abstract] OR "Paeonia lactiflora" [MeSH])) AND (("iron metabolism" [Title/Abstract] OR "ferroptosis" [MeSH] OR "lipid peroxidation" [Title/Abstract]) OR ("JAK-STAT pathway" OR "PI3K/AKT" OR "MAPK/NF-κB" OR "GPX4" [Title/Abstract]) AND ("randomized controlled trial" [Publication Type] OR "in vitro" [Title/Abstract] OR "in vivo" [Title/Abstract] OR "clinical study" [Title/Abstract])).
Ligusticum chuanxiong: and P. lactiflora modulate iron homeostasis by suppressing hepcidin and enhancing ferroportin, inhibit ferroptosis via GPX4 activation and System Xc- upregulation, and mitigate oxidative stress/inflammation through ROS scavenging and NF-κB suppression, collectively reducing atherosclerotic plaque instability.
Chuanxiong and Chishao demonstrate significant potential as therapeutic agents for AS by targeting iron metabolism and ferroptosis. Their traditional use in TCM is supported by modern pharmacological evidence, highlighting their potential for integration into modern therapeutic frameworks.